A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
- PMID: 28249076
- DOI: 10.1001/jamapsychiatry.2017.0080
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Abstract
Importance: Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of ketamine as an off-label treatment for mood and other psychiatric disorders.
Observations: This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge. While ketamine may be beneficial to some patients with mood disorders, it is important to consider the limitations of the available data and the potential risk associated with the drug when considering the treatment option.
Conclusions and relevance: The suggestions provided are intended to facilitate clinical decision making and encourage an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering the limited information that is currently available. This article provides information on potentially important issues related to the off-label treatment approach that should be considered to help ensure patient safety.
Comment in
-
Use of Ketamine in Clinical Practice: A Time for Optimism and Caution.JAMA Psychiatry. 2017 Apr 1;74(4):405-406. doi: 10.1001/jamapsychiatry.2017.0078. JAMA Psychiatry. 2017. PMID: 28249064 No abstract available.
-
Ketamine for the Treatment of Depression-Reply.JAMA Psychiatry. 2017 Sep 1;74(9):971-972. doi: 10.1001/jamapsychiatry.2017.1776. JAMA Psychiatry. 2017. PMID: 28700772 No abstract available.
-
Ketamine for the Treatment of Depression.JAMA Psychiatry. 2017 Sep 1;74(9):971. doi: 10.1001/jamapsychiatry.2017.1779. JAMA Psychiatry. 2017. PMID: 28700777 No abstract available.
-
Ketamine for the Treatment of Depression.JAMA Psychiatry. 2017 Sep 1;74(9):970-971. doi: 10.1001/jamapsychiatry.2017.1773. JAMA Psychiatry. 2017. PMID: 28700782 No abstract available.
-
Ketamine for the Treatment of Depression.JAMA Psychiatry. 2017 Sep 1;74(9):970. doi: 10.1001/jamapsychiatry.2017.1770. JAMA Psychiatry. 2017. PMID: 28700802 No abstract available.
Similar articles
-
Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.J Clin Psychiatry. 2018 Jul 24;79(4):17m11731. doi: 10.4088/JCP.17m11731. J Clin Psychiatry. 2018. PMID: 30063304 Free PMC article. Clinical Trial.
-
The promise of ketamine for treatment-resistant depression: current evidence and future directions.Ann N Y Acad Sci. 2015 May;1345(1):47-58. doi: 10.1111/nyas.12646. Epub 2015 Feb 3. Ann N Y Acad Sci. 2015. PMID: 25649308 Free PMC article. Review.
-
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.Am J Psychiatry. 2016 Aug 1;173(8):816-26. doi: 10.1176/appi.ajp.2016.16010037. Epub 2016 Apr 8. Am J Psychiatry. 2016. PMID: 27056608 Clinical Trial.
-
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.J Psychopharmacol. 2021 Feb;35(2):128-136. doi: 10.1177/0269881120954048. Epub 2020 Oct 11. J Psychopharmacol. 2021. PMID: 33040665
-
A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect.J Clin Psychopharmacol. 2016 Feb;36(1):50-6. doi: 10.1097/JCP.0000000000000441. J Clin Psychopharmacol. 2016. PMID: 26658082 Review.
Cited by
-
Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGlu3) impairs postsynaptic plasticity and modulates affective behaviors.Neuropsychopharmacology. 2021 Nov;46(12):2148-2157. doi: 10.1038/s41386-021-01041-2. Epub 2021 May 25. Neuropsychopharmacology. 2021. PMID: 34035469 Free PMC article.
-
Intraoperative Low-Dose S-Ketamine Reduces Depressive Symptoms in Patients with Crohn's Disease Undergoing Bowel Resection: A Randomized Controlled Trial.J Clin Med. 2023 Feb 1;12(3):1152. doi: 10.3390/jcm12031152. J Clin Med. 2023. PMID: 36769799 Free PMC article.
-
Lucy in the sky with ketamine: Psychoactive drugs have potential for a major breakthrough in treating depression.EMBO Rep. 2018 Nov;19(11):e47118. doi: 10.15252/embr.201847118. Epub 2018 Oct 15. EMBO Rep. 2018. PMID: 30322861 Free PMC article.
-
Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series.Drug Saf. 2021 Dec;44(12):1365-1374. doi: 10.1007/s40264-021-01120-9. Epub 2021 Oct 26. Drug Saf. 2021. PMID: 34699023 Free PMC article.
-
Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders.Int Clin Psychopharmacol. 2020 Jul;35(4):173-193. doi: 10.1097/YIC.0000000000000314. Int Clin Psychopharmacol. 2020. PMID: 32433254 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical